Living Longer But Losing Our Minds: The Alzheimer’s Emergency
Thanks to medical advances, we’re living longer lives but with that comes rising rates of Alzheimer’s. However, emerging new drugs have the ability to slow cognitive decline—giving hope to millions.
Episode two of season four explores the history of Alzheimer’s, its current challenges, and the promising therapies at the forefront of innovation and investment. You’ll hear from:
- Dr. Asa Abeliovich, Neurologist, Molecular Geneticist, and Founder and CEO at Leal Therapeutics
- Carl Gordon, Managing Partner and Head of Global Private Equity at OrbiMed
- Ham Lee, Co-Head of Healthcare Practice at Cambridge Associates
- Randi Casciano, Director of Global Public Relations at Cambridge Associates
Listen below or wherever you get your podcasts.
Explore more episodes
Listen nowAbout
Unseen Upside: Investments Beyond Their Returns is developed in partnership with PRX, an award-winning podcast media company. Cambridge Associates is a global investment firm that works with endowments, foundations, healthcare systems, pension plans, and private clients to implement and manage custom investment portfolios that aim to generate outperformance and maximize their impact on the world. Cambridge Associates delivers a range of portfolio management services, including outsourced CIO, non-discretionary portfolio management, staff extension, and asset class mandates.
Enjoying the podcast? Subscribe, rate, and review Unseen Upside: Investments Beyond Their Returns on Apple Podcasts and Spotify.
Have an idea for an episode or interested in being a guest? Email unseenupside@cambridgeassociates.com to get involved.